Benzene Ring Containing Patents (Class 514/576)
-
Publication number: 20110319267Abstract: Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are also disclosed. Such compounds have utility for treating or preventing gastrointestinal disorders, including colon cancer, ulcerative colitis and Crohn's disease.Type: ApplicationFiled: September 10, 2009Publication date: December 29, 2011Applicant: Numed International, Inc.Inventor: Nnochiri Ekwuribe
-
Publication number: 20110311528Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.Type: ApplicationFiled: June 22, 2011Publication date: December 22, 2011Applicant: Action MedicinesInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20110306614Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.Type: ApplicationFiled: August 19, 2011Publication date: December 15, 2011Applicants: THE JOHNS HOPKINS UNIVERSITY, CARDIOXYL PHARMACEUTICALS, INC.Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Publication number: 20110301235Abstract: Provided herein are organoselenium compounds and pharmaceutical compositions thereof. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders using the compounds and pharmaceutical compositions provided herein.Type: ApplicationFiled: December 2, 2010Publication date: December 8, 2011Applicant: Alquest Therapeutics, Inc.Inventors: Daniel A. Erlanson, Stig K. Hansen
-
Patent number: 8063242Abstract: (R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.Type: GrantFiled: November 19, 2002Date of Patent: November 22, 2011Assignee: Dompe PHA.R.MA S.p.A.Inventors: Marcello Allegretti, Riccardo Bertini, Cinzia Bizzarri, Maria Candida Cesta, Francesco Colotta
-
Publication number: 20110262550Abstract: A method for treating a skin ailment by applying a personal composition from a collapsible dispenser. The collapsible dispenser includes a collapsible bag at least partially surrounded by an elastically deformable member and, optionally, an outer container body. Potential energy is generated by stretching the elastically deformable member, which is used to dispense the composition in lieu of a propellant or pump. The personal care composition may be a skin care composition, an antifungal, or an enzyme inhibiting composition.Type: ApplicationFiled: April 26, 2010Publication date: October 27, 2011Inventors: Thomas James Klofta, Gary Dean Lavon, Thomas Edward Schulte
-
Publication number: 20110243997Abstract: The present invention provides a film-form preparation having a rapid dissolution profile in the mouth and sufficient film strength, and also having excellent appearance and feel. More specifically, the present invention provides a film-form preparation including: a water-soluble and a polar organic solvent-soluble edible polymer; and polar organic solvent-insoluble drug particles.Type: ApplicationFiled: March 28, 2011Publication date: October 6, 2011Applicant: NITTO DENKO CORPORATIONInventors: Daisuke ASARI, Mitsuhiko HORI, Takuya SHISHIDO
-
Publication number: 20110230562Abstract: The present invention provides an enzymatic and a chemical synthesis of melanins and novel melanins.Type: ApplicationFiled: December 22, 2008Publication date: September 22, 2011Inventors: Earle W. Holmes, Kenneth D. Thompson
-
Publication number: 20110218226Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.Type: ApplicationFiled: March 8, 2011Publication date: September 8, 2011Inventor: MENACHEM SHOHAM
-
Publication number: 20110196040Abstract: The invention relates to pharmaceutical compositions and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate, at least one occlusive agent, and at least one stabilizer.Type: ApplicationFiled: February 17, 2009Publication date: August 11, 2011Applicant: Action Medicines S.L.Inventors: David Osborne, Pramod P. Sarpotdar, Arturo J. Angel, Inigo Saenz De Tejada, Maria Luisa Krauel
-
Patent number: 7972798Abstract: The present invention provides methods for detecting and measuring, in a sample from a subject, the plasma levels of endothelial cell antibodies to diagnose an increased risk of pathological complications, such as visual impairment, associated with diabetes.Type: GrantFiled: December 4, 2008Date of Patent: July 5, 2011Assignee: The United States of America as represented by the Department of Veterans AffairsInventors: Mark B. Zimering, Zui Pan, Janet Alder, Smita Thakker-Varia
-
Publication number: 20110160148Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: ApplicationFiled: June 30, 2010Publication date: June 30, 2011Applicant: THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATIONInventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Elton Jeffrey North
-
Patent number: 7968531Abstract: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.Type: GrantFiled: February 16, 2005Date of Patent: June 28, 2011Assignee: Action Medicines, S.L.Inventors: Pedro Cuevas Sanchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafín Valverde Lopez, Rosa María Lozano Puerto
-
Publication number: 20110144043Abstract: The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.Type: ApplicationFiled: December 11, 2009Publication date: June 16, 2011Applicant: Dana-Farber Cancer InstituteInventor: David A. Frank
-
Publication number: 20110124732Abstract: The present application describes deuterium-enriched disufenton, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: May 19, 2010Publication date: May 26, 2011Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Patent number: 7947851Abstract: The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.Type: GrantFiled: March 29, 2005Date of Patent: May 24, 2011Assignee: Merck Serono SAInventors: Dominique Swinnen, Catherine Jorand-Lebrun, Patrick Gerber, Jerome Gonzalez, Agnes Bombrun
-
Publication number: 20110118303Abstract: The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.Type: ApplicationFiled: April 9, 2009Publication date: May 19, 2011Applicants: EMS S.A., Universidade Estadual Paulista Julio De Mesquita Filho - UNESPInventors: Ednir de Oliveira Vizioli, Chung Man Chin, Renato Farina Menegon, Lorena Blau, Jean Leandro Dos Santos, Maria do Carmo Longo
-
Patent number: 7939561Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable tablet dosage forms. Also provided is packaging that discourages the use of rapidly bioavailable acute pain medications for off-label chronic pain treatment, and that allows such dosage forms to be manufactured and stored for prolonged periods of time.Type: GrantFiled: February 7, 2006Date of Patent: May 10, 2011Assignee: APR Applied Pharma Research s.a.Inventors: Norman D. Schellenger, William R. Maichle, Carl L. Whatley, Jr., Giorgio Reiner, Alberto Reiner
-
Publication number: 20110105543Abstract: This invention relates to novel triaryl derivatives, formula (I), a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein all of X, Y and Z represent CH; or one or two of X, Y and Z represent N; and the others of X, Y and Z represent CH; and R1, R2, R3, R4 and R5. independently of each other, represent hydrogen, halo, tri-fluoromethyl, trifluoromethoxy, cyano, hydroxyl, alkoxy, alkyl, amino or sulfamoyl; or R1 and R2, together with the phenyl ring to which they are attached form an indolyl ring or a benzo-dioxolyl ring; and R3, R4 and R5 are as defined above; and R6 represents amino or nitro, which are found to be modulators of the nicotinic acetylcholine receptors.Type: ApplicationFiled: March 9, 2009Publication date: May 5, 2011Applicant: NeuroSearch A/SInventors: Antonio Nardi, Jeppe Kejser Christensen, Dan Peters
-
Publication number: 20110097422Abstract: A microbicidal disinfecting composition and a method of preparing the same include the use of an acidifying agent that comprises at least one of an alkali metal bisulfate, ammonium bisulfate, or a combination thereof. The composition has broad-spectrum microbicidal properties and does not demonstrate cloudiness or precipitation when prepared, diluted, or otherwise exposed to hard water.Type: ApplicationFiled: October 26, 2010Publication date: April 28, 2011Inventor: John Alex Lopes
-
Patent number: 7928146Abstract: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an ?adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2?, dopamine, morphine, ?-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomisis.Type: GrantFiled: March 18, 2003Date of Patent: April 19, 2011Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K. S. Phillips
-
Publication number: 20110076249Abstract: The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.Type: ApplicationFiled: December 3, 2010Publication date: March 31, 2011Applicant: IRx Therapeutics, Inc.Inventors: John W. Hadden, Paul Naylor
-
Patent number: 7897644Abstract: The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for treating inflammation.Type: GrantFiled: November 6, 2002Date of Patent: March 1, 2011Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Gérard Moinet, Dominique Marais, Philippe Maizeray
-
Publication number: 20110039705Abstract: A method of producing a granular agrochemical composition having excellent handling properties, wherein a powdered agrochemical wettable composition or powdered agrochemical water-soluble composition is converted in form to a granular agrochemical composition, without altering the formulation thereof. The method of producing a granular agrochemical composition includes: treating a powdered agrochemical wettable composition or powdered agrochemical water-soluble composition by (1) a step of adding water, kneading, extruding and drying, (2) a step of adding water, granulating by stirring and drying, (3) a step of adding water, kneading and spray-drying, (4) a step of adding water and performing fluidized bed granulation, or (5) a step of pressure molding the powdered agrochemical wettable composition or powdered agrochemical water-soluble composition; followed by (a) a step of performing microgranulation by grinding, and if necessary, (b) a step of performing grain size regulation by sieving.Type: ApplicationFiled: April 23, 2009Publication date: February 17, 2011Inventors: Yoshihisa Endo, Satoru Yamamura
-
Publication number: 20110033505Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: ApplicationFiled: August 16, 2010Publication date: February 10, 2011Applicant: RELYPSA, INC.Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
-
Patent number: 7879907Abstract: Novel 3-phenylpropanoic acid compounds have the general formula (I) below: and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or lipid metabolism-related diseases), or, alternatively, into cosmetic compositions.Type: GrantFiled: December 7, 2009Date of Patent: February 1, 2011Assignee: Galderma Research & DevelopmentInventors: Jean-Guy Boiteau, Laurence Clary, Jean-Claude Pascal, Veronique Parnet
-
Patent number: 7858664Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: December 23, 2004Date of Patent: December 28, 2010Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Publication number: 20100311791Abstract: The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.Type: ApplicationFiled: December 28, 2007Publication date: December 9, 2010Inventors: Ramin Najafi, Rakesh K. Jain, Timothy P. Shiau, Eddy Low, Satheesh K. Nair
-
Publication number: 20100298308Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: ApplicationFiled: November 14, 2006Publication date: November 25, 2010Inventors: Dianqing (Dan) Wu, Dakai Liu, James J. Donegan
-
Patent number: 7838554Abstract: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: GrantFiled: June 9, 2009Date of Patent: November 23, 2010Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7803776Abstract: Provided are combinations of inhibitors of dipeptidyl peptidase IV (DP IV) and of enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) and use of the same to obtain a more than additive to superadditive inhibition for the treatment of arteriosclerosis, for the treatment of allergic reactions of the type I according to the Gell and Coombs classification and for the treatment of dermatological diseases with follicular and epidermal hyperkeratoses and an enhanced proliferation of keratinocytes.Type: GrantFiled: June 11, 2007Date of Patent: September 28, 2010Assignee: Institut fur Medizintechnologie Magdeburg (IMTM) GmbHInventors: Siegfried Ansorge, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Robert Vetter, Harald Gollnick
-
Publication number: 20100239692Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.Type: ApplicationFiled: September 19, 2008Publication date: September 23, 2010Inventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin
-
Publication number: 20100227928Abstract: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.Type: ApplicationFiled: March 5, 2009Publication date: September 9, 2010Inventors: Kamran HOSSEINI, Lyle M. BOWMAN, Erwin C. SI, Stephen Pham
-
Publication number: 20100227009Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.Type: ApplicationFiled: May 18, 2010Publication date: September 9, 2010Applicants: BIOPROSPECT LIMITED, UNIVERSITY OF WESTERN SYDNEYInventors: Robert Neil Spooner-Hart, Albert Habib Basta
-
Patent number: 7786176Abstract: A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na+) and calcium (Ca2+) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.Type: GrantFiled: July 29, 2005Date of Patent: August 31, 2010Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Stephanie M. Martin, Lei Huang, Shu-Ping Yang, Yanbin Huang, Julie Villanueva, Sharon Linda Greene, Kelly Arehart, Curtis Sayre, Robert B. Johnson
-
Publication number: 20100184730Abstract: The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.Type: ApplicationFiled: February 26, 2010Publication date: July 22, 2010Inventors: Chi B. Vu, Jean E. Bemis, Michael R. Jirousek, Jill C. Milne, Jesse J. Smith
-
Patent number: 7759370Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.Type: GrantFiled: August 1, 2007Date of Patent: July 20, 2010Assignee: Praecis PharmaceuticalsInventors: Ghotas Evindar, Hongfeng Deng, Sylvie Bernier, Gang Yao, Aaron Coffin, Hongfang Yang
-
Patent number: 7759394Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.Type: GrantFiled: June 16, 2006Date of Patent: July 20, 2010Assignee: APR Applied Pharma Research SAInventors: Giorgio Reiner, Alberto Reiner, Andreas Meyer
-
Publication number: 20100152296Abstract: The main goal of the present invention is the development of a polymerizable material for isolation and protection of the gums and generally the soft tissues of the oral cavity. For better protection during various procedures of the dental surfaces. The composition of the material can contain many other substances that strengthen its qualities and protective action. Such substances can be various substances that have antioxidative, sedative, anti-inflammatory, analgesic, anti-irritant action etc.Type: ApplicationFiled: February 9, 2007Publication date: June 17, 2010Applicant: Klox Technologies Inc.Inventors: Vassilios Marmarinos, Paschalis Paschalakis, Irene Tseti
-
Publication number: 20100129455Abstract: The present invention provides fine silicon-containing glass beads each having one or more cavities therein and containing nanoparticles in a glass phase of each of the silicon-containing glass beads, and a method of producing such glass beads, and also provides silicon-containing glass beads containing nanoparticles, which may be identical to or different from the nanoparticles in the glass phase, and a functional material such as pharmaceutical molecules (e.g., materials having fluorescent properties, magnetic properties, drug effects, etc.), and a method of producing such glass beads. The present invention relates to silicon-containing glass beads each having one or more cavities therein and having an average particle diameter of 20 nm to 1 ?m, the silicon-containing glass beads containing nanoparticles A in the silicon-containing glass phase, and also containing a functional material in the cavity.Type: ApplicationFiled: October 13, 2009Publication date: May 27, 2010Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Norio MURASE, Ping YANG, Masanori ANDO
-
Patent number: 7700125Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.Type: GrantFiled: February 7, 2006Date of Patent: April 20, 2010Assignee: Kowa Pharmaceuticals America, Inc.Inventors: Giorgio Reiner, Alberto Reiner
-
Publication number: 20100092578Abstract: The invention involves PKC? signaling. The invention provides, for example, transgenic animals, inhibitors of PKC? signaling, methods for inhibiting PKC? signaling, methods for identifying inhibitors of PKC? signaling, and methods for diagnosing cancer.Type: ApplicationFiled: October 1, 2009Publication date: April 15, 2010Inventors: Alan P. Fields, Nicole Renee Murray, Melody Lee Stallings-Mann, Lee Jamieson
-
Publication number: 20100087541Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: ApplicationFiled: August 31, 2009Publication date: April 8, 2010Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Kirvin L. Hodge, Shalini Sharma, Albert C. Lee, Reid W. von Borstel
-
Patent number: 7687542Abstract: The present invention relates to excipients for the production of rapidly bioavailable solid oral dosage forms of diclofenac. In particular, the invention relates to the use of excipients that promote the bioavailability of such formulations, including alkaline buffering agents, gas forming excipients, hygroscopic excipients, water soluble diluents, wetting agents, and particular pharmaceutically acceptable salts.Type: GrantFiled: February 10, 2006Date of Patent: March 30, 2010Assignee: Kowa Pharmaeuticals America, Inc.Inventors: Giorgio Reiner, Alberto Reiner
-
Publication number: 20100041759Abstract: Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in a gradient, decreasing the side effects associated with rapidly elevated blood levels. In another embodiment, the drug is bound to an ion-exchange resin, which can be suspended in a liquid or incorporated into a matrix for delayed, sustained and/or pulsed release. Dosage unit forms may be tablets, gels, liquids, capsules, beads, microparticles, films or lozenges. Multi-phase delivery can also be achieved through the use of a kit that provides for dosage escalation. The formulations are useful in the treatment of one or more symptoms of coughs, colds, sinusitis and other respiratory illnesses.Type: ApplicationFiled: October 21, 2009Publication date: February 18, 2010Inventors: Glynn Wilson, Matthew F. Heil
-
Publication number: 20100009991Abstract: The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.Type: ApplicationFiled: December 13, 2007Publication date: January 14, 2010Applicant: Astellas Pharma Inc.Inventors: Tadashi Terasaka, Tatsuya Zenkoh, Hisashi Hayashida, Hiroshi Matsuda, Junji Sato, Yoshimasa Imamura, Hiroshi Nagata, Norio Seki, Yoshiyuki Tenda, Mamoru Tasaki, Masahiro Takeda, Seiichiro Tabuchi, Minoru Yasuda, Kazunori Tsubaki
-
Patent number: 7632523Abstract: An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.Type: GrantFiled: September 11, 2006Date of Patent: December 15, 2009Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Navid Omidbakhsh
-
Publication number: 20090275514Abstract: Provided are compositions and methods of treating inflammation of the heart of a subject diagnosed with inflammation of the heart, comprising administering to the subject an effective amount of an inhibitor of Calmodulin Kinase II, whereby the administration of the inhibitor treats inflammation of the heart in the subject. Also provided are compositions and methods of preventing inflammation of the heart of a subject, comprising administering to the subject an effective amount of an inhibitor of Calmodulin Kinase II, whereby the administration of the inhibitor prevents inflammation of the heart in the subject.Type: ApplicationFiled: April 30, 2009Publication date: November 5, 2009Inventors: Mark E. Anderson, Madhu V. Singh
-
Publication number: 20090264532Abstract: Carboxylic anhydrides are highly suitable as additive for industrial materials, cosmetics, pharmaceutics and foodstuffs, in particular beverages, for protecting them against attack and/or destruction by microorganisms.Type: ApplicationFiled: July 18, 2007Publication date: October 22, 2009Applicant: LANXESS DEUTSCHLAND GMBHInventors: Johannes Kaulen, Erasmus Vogl, Edwin Ritzer, Manfred Hoffmann
-
Patent number: RE41279Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.Type: GrantFiled: March 2, 2006Date of Patent: April 27, 2010Assignee: Ecolab Inc.Inventors: David D. McSherry, Francis L. Richter